Shin Nippon Biomedical Laboratories, Ltd. (JP:2395) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Shin Nippon Biomedical Laboratories’ subsidiary, Satsuma Pharmaceuticals, has received FDA acceptance for the resubmission of its NDA for STS101, a novel treatment for acute migraine. This milestone aligns with SNBL’s financial forecasts for the fiscal year ending March 2025, as the U.S. market for such treatments exceeds $1 billion.
For further insights into JP:2395 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Paramount (NASDAQ:PARA) Reduces Its Macy’s Thanksgiving Parade Connection
- Ford (NYSE:F) Slides as Trump Threatens to Hit Mexico with Tariffs
- Intel’s (NASDAQ:INTC) CHIPS Act Payout Will Be $7.87 Billion
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
